MK3475-361
Laufzeit: 01.01.2017 - 31.12.2021
Kurzfassung
A phase III randomized, controlled clinical trial of Pembrolizumab with or without platinum-based combination chemotherapy versus chemotherapy in subjects with advanced urothelial carcinoma
Laufzeit: 01.01.2017 - 31.12.2021
A phase III randomized, controlled clinical trial of Pembrolizumab with or without platinum-based combination chemotherapy versus chemotherapy in subjects with advanced urothelial carcinoma
